Fibroblast growth factor 4 gene therapy for chronic ischemic heart disease.

Abstract

Therapeutic myocardial angiogenesis and arteriogenesis represent a novel treatment strategy for patients with angina refractory to traditional medical and surgical therapies. The fibroblast growth factors are a family of proteins that are known mediators of angio-/arteriogenesis. Based on promising preclinical animal data, a series of four randomized placebo-controlled clinical trials have been conducted to determine the safety and efficacy of local delivery of fibroblast growth factor 4 with the use of adenovirus-vector-mediated gene transfer to induce myocardial angio-/arteriogenesis in patients with stable angina. This review describes the scientific rationale underlying these clinical trials, provides an overview of their results, and discusses the implications for future studies.

• Authors: Navin K Kapur, Jeffrey J Rade
• Journal: Trends in cardiovascular medicine (Trends Cardiovasc Med) Vol. 18 Issue 4 Pg. 133-41 (May 2008) ISSN: 1050-1738 [Print] United States
• PMID: 18555186 (Publication Type: Journal Article, Review)

Chemical References

• Fibroblast Growth Factor 4

Topics

• Adenoviridae (genetics)
• Animals
• Chronic Disease
• Clinical Trials as Topic
• Collateral Circulation
• Coronary Circulation
• Fibroblast Growth Factor 4 (genetics, metabolism)
• Gene Transfer Techniques
• Genetic Therapy (adverse effects, methods)
• Genetic Vectors
• Humans
• Myocardial Ischemia (genetics, metabolism, physiopathology, therapy)
• Neovascularization, Physiologic
• Patient Selection
• Time Factors
• Treatment Outcome